PD-L1 and intratumoral immune response in breast cancer
| dc.contributor.author | Wang, Zhi-Qiang | |
| dc.contributor.author | Milne, Katy | |
| dc.contributor.author | Derocher, Heather | |
| dc.contributor.author | Webb, John R. | |
| dc.contributor.author | Nelson, Brad H. | |
| dc.contributor.author | Watson, Peter H. | |
| dc.date.accessioned | 2018-11-02T08:27:04Z | |
| dc.date.available | 2018-11-02T08:27:04Z | |
| dc.date.copyright | 2017 | en_US |
| dc.date.issued | 2017 | |
| dc.description.abstract | Purpose: PD-L1 is thought to play an important role in the antitumor immune response. In this study, we investigated the expression of PD-L1 within breast tumor subsets to better define its prognostic significance. Methods: Immunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype. Results: Across the entire cohort, PD-L1 tumor cell expression was observed in 73/443 (16.5%) cases and associated with known indicators of poor prognosis, including low patient age, high tumor grade, ER/PR negative status, but not with outcome. However, in the Triple Negative breast cancer subset PD-L1 was associated with better recurrence free survival (RFS) especially within the Basal-like subset (Hazard ratio = 0.39, 95% CI = 0.22 - 0.86, p = 0.018). Combined PD-L1/epithelial CD8 positive status was also strongly associated with better RFS and OS (Hazard ratio = 0.12, 95% CI = 0.10 - 0.71, p = 0.010 and Hazard ratio = 0.11, 95% CI = 0.11 - 0.68, p = 0.006 respectively) in the Basal-like subgroup. Conclusions: PD-L1 expression is associated with better patient survival in Basal-like breast cancer. | en_US |
| dc.description.reviewstatus | Reviewed | en_US |
| dc.description.scholarlevel | Faculty | en_US |
| dc.description.sponsorship | This study was sustained by a grant to P.H.W from the Canadian Cancer Society Research Institute (#702375). | en_US |
| dc.identifier.citation | Wang, Z.; Milne, K.; Derocher, H.; Webb, J.R.; Nelson, B.H.; & Watson, P.H. (2017). PD-L1 and intratumoral immune response in breast cancer. Oncotarget, 8(31), 51641-51651. https://doi.org/10.18632/oncotarget.18305 | en_US |
| dc.identifier.uri | https://doi.org/10.18632/oncotarget.18305 | |
| dc.identifier.uri | http://hdl.handle.net/1828/10242 | |
| dc.language.iso | en | en_US |
| dc.publisher | Oncotarget | en_US |
| dc.subject | PD-L1 | en_US |
| dc.subject | CD4 | en_US |
| dc.subject | CD8 | en_US |
| dc.subject | CD68 | en_US |
| dc.subject | breast cancer | en_US |
| dc.title | PD-L1 and intratumoral immune response in breast cancer | en_US |
| dc.type | Article | en_US |